Key Highlights
- $33.5 million additional raised: Apollo Therapeutics completes the second close of its Series C financing, bringing the 2023 total to $260 million.
- Broad and diversified pipeline: Over 20 therapeutic programs with multiple assets set to enter clinical trials in early 2024.
- Strong backing: Led by Patient Square Capital with participation from new and existing high-profile investors including M&G plc and major US public pension plans.
Source: Business Wire
Notable Quote
- “We are delighted to have completed the second close of our Series C financing in December and thank existing investors for their additional support, as well as welcoming new shareholders to the Company. We are progressing a broad and diversified pipeline of over 20 uncorrelated therapeutic programs, with multiple assets about to enter the clinic in early 2024. We look forward to an exciting year ahead.” – Dr. Richard Mason, Chief Executive Officer at Apollo Therapeutics
SoH's Take
The successful close of Apollo’s Series C financing round is a testament to the company’s robust approach and promising pipeline. With a substantial $260 million raised in 2023, Apollo is well-positioned to advance its diversified portfolio of therapeutic programs, reflecting investor confidence and the company’s strategic hub-and-spoke model. The participation of heavyweight investors underscores the market’s belief in Apollo’s innovative approach to drug discovery and development. As the biopharmaceutical sector continues to evolve, Apollo’s progress will be closely watched as they move multiple assets into clinical trials in the coming year, marking an exciting phase in their journey to translate fundamental medical research into groundbreaking medicines.
